全球血管内主动脉治疗注册研究中胸主动脉疾病的血管内治疗
GREAT是一项国际前瞻性多中心注册研究,收集W. L. Gore胸腹主动脉内移植物真实世界数据。本分析评估5014例入组患者中578例胸主动脉疾病患者行胸主动脉腔内修复(TEVAR)后5年生存与器械性能,按病理分组,结果显示GORE TAG支架移植物耐久性良好,无支架压缩或断裂事件,主动脉相关死亡免除率高。
要点
- 578例胸主动脉疾病患者按病理分为胸主动脉瘤239例、主动脉夹层203例、弓部26例、其他110例。
- 术后30天全因死亡免除率99.6%,31天至5年66.4%;主动脉相关死亡免除率分别为97.7%和94.6%。
- 5年内无支架压缩或断裂事件,再干预率30天7.3%、5年12.4%。
核心结论
- 数据表明GORE TAG顺应性胸主动脉支架移植物治疗胸主动脉疾病具有耐久性并支持其应用,包括无支架压缩/断裂事件和较高的主动脉相关死亡免除率。
- 作者认为GREAT计划进行10年随访分析将有益。
研究设计与样本
- 国际前瞻性多中心注册研究(GREAT),收集W. L. Gore胸主动脉和腹主动脉内移植物性能的真实世界数据。
- 2010年8月至2016年10月共入组5014例患者,本分析纳入578例因胸主动脉疾病接受TEVAR的患者。
- 按常见病理分组:胸主动脉瘤(n=239)、胸主动脉夹层(n=203)、弓部(n=26)、其他(n=110)。
- 人群平均年龄66.1±12.8岁,男性占64.7%。
主要发现
- 手术生存率为99.7%。
- 总体组从索引手术至30天和31天至5年,Kaplan-Meier估计的全因死亡免除率分别为99.6%和66.4%,主动脉相关死亡免除率分别为97.7%和94.6%。
- 主动脉破裂率30天为0.5%(n=3),5年内为1.4%(n=8)。
- 卒中30天为1.9%(n=11),5年为3.6%(n=20);脊髓缺血事件30天为1.6%(n=9),5年为0.5%(n=3)。
- 再干预30天为7.3%(n=42),5年内为12.4%(n=69);30天内漏为2.1%(n=12),5年内为8.3%(n=40);30天支架移位1例(0.2%,动脉瘤组),5年内无报告;5年内无支架压缩或断裂。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Global Registry for Endovascular Aortic Treatment (GREAT) is an international prospective multicenter registry collecting real-world data on performance of W. L. Gore thoracic and abdominal aortic endografts. This analysis evaluated the long-term differences in patient survival and device performance in patients undergoing thoracic endovascular aortic repair (TEVAR) for any thoracic aortic pathology. METHODS: From August 2010 to October 2016, 5014 patients were enrolled in GREAT. The population of interest was comprised of only patients treated for thoracic aortic pathologies. Through 5 years, primary outcomes were all-cause and aortic-related mortality, stroke, aortic rupture, endoleaks, migration, fracture, compression, paraplegia, and any reintervention through 5 years, grouped by pathology. Secondary outcomes were reintervention rate and freedom from serious device- and aortic-related events. RESULTS: The 578 patients with thoracic aortic pathologies enrolled in GREAT and identified for this analysis were categorized by common pathologies: thoracic aneurysm (n = 239), thoracic dissection (n = 203), arch (n = 26), and other (n = 110). The mean age of this population was 66.1 ± 12.8 years, and 64.7% were male. Procedure survival was 99.7%. In the overall group, at index procedure to 30 days and 31 days to 5 years, Kaplan-Meier estimates of freedom from all-cause mortality were 99.6% and 66.4%, respectively, and for aortic-related mortality were 97.7% and 94.6%, respectively. Aortic rupture rate was 0.5% (n = 3) at 30 days and 1.4% (n = 8) through 5 years. Stroke and spinal cord ischemic events were 1.9% (n = 11) and 1.6% (n = 9) at 30 days and at 5 years were 3.6% (n = 20), 0.5% (n = 3), respectively. Reinterventions were required in 7.3% (n = 42) at 30 days and 12.4% (n = 69) through 5 years. The number of patients with endoleaks at 30 days was 2.1% (n = 12): n = 3 (1.1%) for each of types IA, 1B, and II; n = 2 (0.3%) for type III; and n = 4 (0.7%) for unspecified. Through 5 years, the percentage of patients was 8.3% (n = 40): n = 15 (3.1%) for type IA; n = 10 (2.1%) for type IB; n = 11 (2.3%) for type II; and n = 9 (1.9%) for unspecified. One patient (0.2%) had stent migration at 30 days (aneurysm group); none were reported through 5 years. There were no incidents of stent compression or fracture from index procedure through 5 years. CONCLUSIONS: Data herein demonstrates durability and support for treatment of thoracic aortic disease with the GORE TAG conformable thoracic stent graft, including no incidents of stent compression/fracture and high freedom from aortic-related mortality. The planned analysis of follow-up to 10 years in GREAT will be beneficial.
引用
- Gable DR, Verhoeven E, Trimarchi S, et al. Endovascular treatment for thoracic aortic disease from the Global Registry for Endovascular Aortic Treatment. J Vasc Surg. 2023. PMID: 38154605. doi:10.1016/j.jvs.2023.12.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。